$0

FDA Accepts Legend’s LB2102 (DLL-3 CAR-T) IND in SCLC

On Monday, November 21, Legend announced (press release) that the FDA has accepted the IND for LB2102 (autologous DLL-3 CAR-T) in extensive stage small cell lung cancer (SCLC). Below, Celltelligence provides insights on LB2102’s IND clearance, discusses potential competition, and highlights how CAR-T therapies could succeed where AbbVie previously failed when targeting DLL-3.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.